Douglas Miehm
Stock Analyst at RBC Capital
(1.96)
# 2,890
Out of 4,784 analysts
46
Total ratings
38.89%
Success rate
-6.99%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.60 | +733.33% | 1 | Mar 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $22 → $18 | $14.13 | +27.39% | 12 | Feb 20, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $11 → $10 | $6.48 | +54.32% | 19 | Jan 30, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $141 → $143 | $107.62 | +32.87% | 5 | Dec 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $8.29 | -3.50% | 9 | Feb 16, 2024 |
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.60
Upside: +733.33%
Bausch + Lomb
Feb 20, 2025
Maintains: Outperform
Price Target: $22 → $18
Current: $14.13
Upside: +27.39%
Bausch Health Companies
Jan 30, 2025
Maintains: Sector Perform
Price Target: $11 → $10
Current: $6.48
Upside: +54.32%
Ligand Pharmaceuticals
Dec 11, 2024
Maintains: Outperform
Price Target: $141 → $143
Current: $107.62
Upside: +32.87%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $8.29
Upside: -3.50%